Floatz logo

BARDOXOLONE METHYL ESTER

Idiopathic Interstitial Pneumonia

BiogenSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Idiopathic Interstitial Pneumonia cohort.

Asset / SponsorPhaseRating
5-PYRIMIDINECARBOXAMIDE, 2-((1,1-DIMETHYLETHYL)AMINO)-4-(((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYL)AMINO)-
Celgene
Phase 2CCC
FAPi-46
University of California, Los Angeles
Early Phase 1C

Same molecule, other indications

BARDOXOLONE METHYL ESTER is also rated in:

pulmonary hypertensionDormant
B
Indicative ·
57 / 100
View asset →
pulmonary arterial hypertensionDormant
B
Indicative ·
57 / 100
View asset →
interstitial lung diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →